StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine™”.
| December 06, 2023 | Timely Disclosure Information | StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation |
|---|---|---|
| December 04, 2023 | Timely Disclosure Information | StemRIM Announces Conclusion of Agreement for the Initiation of a Phase2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy |
| November 16, 2023 | Timely Disclosure Information | [Delayed]StemRIM Announces Extension of the Tripartite Collaborative Research Agreement Updated on January 24, 2023 |
| November 16, 2023 | Timely Disclosure Information | [Delayed]StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock |
| October 27, 2023 | Timely Disclosure Information | [Delayed]StemRIM Announces Change of Representative Directors |
| April 25, 2023 | NEWS Release |
|---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”.
“Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.
